SILK has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
SILK has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Silk Road Medical's Cash per Share for the quarter that ended in Mar. 2024 was $4.42.
The historical data trend for Silk Road Medical's Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silk Road Medical Annual Data | ||||||||||||||||
Trend | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||
Cash per Share | Get a 7-Day Free Trial | 2.90 | 4.31 | 3.15 | 5.57 | 4.63 |
Silk Road Medical Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cash per Share | Get a 7-Day Free Trial | 4.88 | 4.85 | 4.96 | 4.63 | 4.42 |
This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.
Silk Road Medical's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 181.474 | / | 39.2 | |
= | 4.63 |
Silk Road Medical's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:
Cash per Share | = | Cash, Cash Equivalents, Marketable Securities | / | Shares Outstanding (EOP) |
= | 174.462 | / | 39.4 | |
= | 4.42 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silk Road Medical (NAS:SILK) Cash per Share Explanation
Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.
Thank you for viewing the detailed overview of Silk Road Medical's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Chas Mckhann | director, officer: Chief Executive Officer | 1555 ADAMS DRIVE, C/O INTERSECT ENT, INC., MENLO PARK CA 94025 |
Marie L. Jones | officer: CAO and VP, Finance | 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
Lucas W. Buchanan | officer: Chief Financial Officer | C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
Kevin M Klemz | officer: EVP/Chief Legal Officer/Sec. | 9600 54TH AVENUE NORTH, SUITE 100, PLYMOUTH MN 55442 |
Andrew S. Davis | officer: Chief Commercial Officer | C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
Erica J. Rogers | director, officer: President and CEO | C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
Elizabeth H Weatherman | director | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Richard Ruedy | officer: EVP Clin & Reg. Affairs and QA | C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
Tony M. Chou | director | C/O SILK ROAD MEDICAL, INC., 1213 INNSBRUCK DRIVE, SUNNYVALE CA 94089 |
Tanisha Carino | director | C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210 |
Kevin J. Ballinger | director | C/O BOSTON SCIENTIFIC CORPORATION, 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234 |
Rick D Anderson | director | 3600 N CAPITAL OF TEXAS HWY, SUITE B180, AUSTIN TX 78746 |
Donald Zurbay | director | C/O ST. JUDE MEDICAL, INC., ONE ST JUDE MEDICAL DRIVE, ST. PAUL MN 55117 |
Warburg Pincus Partners Gp Llc | 10 percent owner | C/O WARBURG PINCUS LLC, 450 LEXINGTON AVENUE, NEW YORK NY 10017 |
Warburg Pincus & Co. | 10 percent owner | 450 LEXINGTON AVENUE, NEW YORK, NY NY 100173147 |
From GuruFocus
By Value_Insider Value_Insider • 10-25-2022
By GuruFocus Research GuruFocus Editor • 12-15-2022
By Marketwired • 11-02-2023
By Marketwired • 10-11-2023
By sperokesalga sperokesalga • 05-04-2023
By Value_Insider Value_Insider • 11-03-2022
By Marketwired • 08-01-2023
By Value_Insider Value_Insider • 10-19-2022
By GlobeNewswire GlobeNewswire • 12-28-2022
By GuruFocus Research • 11-08-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.